Table 9.

Comparison of dose-dense temozolomide trials: adverse events

Adverse event	Grade	Brandes153	Strik155	Abacioglu156	Berrocal157	Norden154	Sahinbas23
	NOP	33	18	16	47	55	140
Total events	I–II	122%	N/A	44%	194%	N/A	34%
	III–IV	76%	49%	92%	45%	60%	0%
	χ2	123 721	72 196	141 308	70 654	100 593
	p Value	<0.00001	<0.00001	<0.00001	<0.00001	<0.00001
Lymphopoenia	I–II	21%		12%	55%		0%
	III–IV	24%	14%	80%	28%	38%	0%
Leucopenia	I–II	21%		20%	28%		0%
	III–IV	24%	14%	4%	2%	5%	0%
Neutropaenia	I–II	9%			17%		0%
	III–IV	12%			2%	4%	0%
Thrombocytopenia	I–II	3%		8%	19%		0%
	III–IV	3%	5%	8%	11%	4%	0%
Anaemia	I–II	26%		4%			0%
	III–IV	3%				2%	0%
Nausea/vomiting	I–II	6%			26%		4%
	III–IV	3%			2%	2%	0%
Fatigue	I–II						4%
	III–IV					5%	0%
Constipation/diarrhoea	I–II	24%			15%		0%
	III–IV	3%					0%
Infection	I–II	12%					0%
	III–IV	3%	5%				0%
Headache	I–II						4%
Skin reactions	I–II						12%
Asthenia	I–II				17%		10%
Gastrointestinal	I–II				17%		0%
	III–IV		10%				0%

N/A, not available.